한국여성에서 폐경 후 Drospirenone 2 mg과 17-β-Estradiol 1 mg 투여의 혈압 및 체중에 대한 효과
Effects of Drospirenone 2 mg with 17-β-Estradiol 1 mg on blood pressure and body weight in postmenopausal Korean women
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
목적: 폐경 후 한국 여성에서 Drospirenone 2 mg (DRSP)과 17-β-Estradiol 1 mg (E2) 투여의 혈압 및 체중에 대한 효과를 평가하였다. 연구 방법: DRSP/E2 투여 전과 3개월 후에 혈압과 체중을 측정하였다. DRSP/E2 투여 전 혈압이 정상혈압 (group 1, 대조군)과 높은정상혈압 (group 2)인 군의 혈압과 체중의 변화를 비교하였으며, 항고혈압제를 복용 중인 고혈압 환자로 DRSP/E2를 추가 투여한 군 (group 3)과 투여하지 않은 군 (group 4, 대조군)의 혈압과 체중도 비교하였다. 결과: Group 1의 평균 수축기 및 이완기 혈압은 변화 없었으나 (P=0.152/P=0.088), group 2의 평균 수축기 및 이완기 혈압은 유의하게 감소하였다 (P<0.001/P=0.002). Group 3의 평균 수축기 및 이완기 혈압은 유의하게 감소하였으며 (P<0.001/P<0.001), group 4의 평균 수축기 및 이완기 혈압도 유의하게 감소하였다 (P=0.002/P<0.001). 그러나 group 3의 혈압 감소가 group 4보다 유의하게 컸다 (P=0.041/P=0.024). DRSP/E2 투여 전, 후 체중은 모든 군 유의한 변화는 없었다. 결론: 폐경 후 한국 여성에서 DRSP/E2의 투여는 높은정상혈압 이상의 혈압을 낮추며, 고혈압 환자에서 항고혈압제와 병용 시 더 크게 낮추는 경향을 보였다. 그러나 투여 전, 후 체중의 유의한 차이는 없었다.
Abstract
Objective: To evaluate effects of Drospirenone 2 mg (DRSP) with 17-β-Estradiol 1 mg (E2) on blood pressure (BP) and body weight in postmenopausal Korean women. Methods: BP and body weight were measured at baseline and 3 months of the treatment. We compared the change in BP and body weight between normotensive (group 1, control) and high-normotensive (group 2) group during treatment. And we compared the change in BP and body weight between hypertensive group receiving anti-hypertensive with (group 3) and without (group 4, control) DRSP/E2 during treatment. Results: The mean systolic BP/diastolic BP of group 1 was not significantly decreased from baseline (116.9/75.0 mmHg) after treatment with DRSP/E2 for 3 months (116.1/73.2 mmHg) (P<0.152/P=0.088), however that of group 2 was significantly decreased from baseline (128.8/81.8 mmHg) after treatment with DRSP/E2 for 3 months (126.2/79.3 mmHg) (P<0.001/P=0.002). The mean systolic BP/diastolic BP of group 3 was significantly decreased from baseline (133.5/82.5 mmHg) after treatment with DRSP/E2 for 3 months (129.3/77.9 mmHg) (P<0.001/P<0.001), and that of group 4 was also significantly decreased from baseline (133.2/80.7 mmHg) after treatment with DRSP/E2 for 3 months (131.0/78.3 mmHg) (P=0.002/P<0.001). However change in the mean systolic BP/diastolic BP of group 3 was greater than that of group 4 (P=0.041/P=0.024). There was no weight change in all four groups. Conclusion: The use of DRSP/E2 showed a tendency to decrease the BP of high-normotensive or above in postmenopausal Korean women, and hypertensive patients receiving anti-hypertensive showed greater decline in BP. However there was no statistical significance in body weight change.
참고문헌 (35)
- Hill K, "The demography of menopause", Maturitas, 23, pp.113~127 (1996)
- 김훈, "혈관운동증상에 대한 비호르몬 치료", 대한폐경학회지, 13, pp.157~163 (2007)
- Sturdee DW, "Is the timing of withdrawal bleeding a guide to endometrial safety during sequential oestrogen-progestagen replacement therapy? UK Continuous Combined HRT Study Investigators", Lancet, 344, pp.979~982 (1994)
- Gambrell RD Jr, "Use of the progestogen challenge test to reduce the risk of endometrial cancer", Obstet Gynecol, 55, pp.732~738 (1980)
- Naftolin F, "Executive Committee of the International Menopause Society. Guidelines for hormone treatment of women in the menopausal transition and beyond", Maturitas, 51, pp.15~20 (2005)
- National Institutes of Health, "National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms", Ann Intern Med, 142(12), pp.1003~1013 (2005)
- Skouby SO, "Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004", 2005 position statements on peri- and postmenopausal hormone replacement therapy, 2005, pp.51, 8~14
- North American Menopause Society, "Recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 position statement of The North American Menopause Society", Menopause, 11(6), pp.589~600 (2004)
- Chobanian AV, "Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure", Hypertension, 42, pp.1206~1252 (2003)
- Staessen J, "The influence of menopause on blood pressure", J Hum Hypertens, 3, pp.427~433 (1989)
- Rosenthal T, "Hypertension in women", J Hum Hypertens, 14, pp.691~704 (2000)
- Wassertheil-Smoller S, "Hypertension and its treatment in postmenopausal women: baseline data from the Women's Health Initiative", Hypertension, 36, pp.780~789 (2000)
- Manson JE, "Estrogen plus progestin and the risk of coronary heart disease", N Engl J Med, 349, pp.523~534 (2003)
- Scuteri A, "Hormone replacement therapy and longitudinal changes in blood pressure in postmenopausal women", Ann Intern Med, 135, pp.229~238 (2001)
- "Effects of estrogen or estrogen", progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen, JAMA, pp.1995, 273[DOI]
- Oelkers WK, "Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure", Steroids, 61, pp.166~171 (1996)
- Duprez D, "Aldosterone and vascular damage", Curr Hypertens Rep, 2, pp.327~334 (2000)
- Rocha R, "Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats", Hypertension, 31(1), pp.451~458 (1998)
- Farquharson CA, "Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin Ⅰ", angiotensin Ⅱ conversion in patients with chronic heart failure, 2000, pp.101, 594~597
- Oelkers W, "Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism", J Clin Endocrinol Metab, 80, pp.1816~1820 (1995)
- Krattenmacher R, "Drospirenone: pharmacology and pharmacokinetics of a unique progestogen", Contraception, 62, pp.29~38 (2000)
- van Seumeren I, "Weight gain and hormone replacement therapy: are women's fears justified?", Maturitas, 34(1), pp.S3~S8 (2000)
- Strothmann A, "Hormone therapy: the European women's perspective", Climacteric, 6, pp.337~346 (2003)
- Gordon T, "Menopause and coronary heart disease. The Framingham Study", Ann Intern Med, 89, pp.157~161 (1978)
- August P, "Initial treatment of hypertension", N Engl J Med, 348, pp.610~617 (2003)
- Oelkers W, "Drospirenone, a progestogen with antimineralocorticoid properties: a short review", Moll Cell Endocrinol, 217, pp.255~261 (2004)
- Oelkers W, "Effect of an oral contraceptive containing drospirenone on the renin-angiotensinaldosterone system in healthy female volunteers", Gynecol Endocrinol, 14, pp.204~213 (2000)
- Lee BS, "Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study", Maturitas, 57, pp.361~369 (2007)
- Preston RA, "Effects of blood pressure reduction on cardiovascular risk estimates in hypertensive postmenopausal women", Climacteric, 10, pp.32~41 (2007)
- Bakken K, "Side-effects of hormone replacement therapy and influence on pattern of use among women aged 45-64 years. The Norwegian Women and Cancer (NOWAC) study 1997", Acta Obstet Gynecol Scand, 83, pp.850~856 (2004)
- Preston RA, "Randomized, placebocontrolled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide", Menopause, 14(3), pp.408~414 (2007)
- Preston RA, "Additive effect of drospirenone", 17-beta- estradiol in hypertensive postmenopausal women receiving enalapril, 2002, pp.15, 816~822
- Reynolds RF, "The role of treatment intentions and concerns about side effects in women's decision to discontinue postmenopausal hormone therapy", Maturitas, 43, pp.183~194 (2002)
- 김주영, "폐경기 여성에서 호르몬 대체요법에 따른 삶의 질에 대한 평가", 대한산부회지, 41, pp.2429~2435 (1998)
- Archer DF, "Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial", Menopause, 12, pp.716~727 (2005)